Reaction
Nail Bed Bleeding reporting signals
As of the last recalculation, Nail Bed Bleeding appears in 559 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is MISOPROSTOL (PRR 54.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Misoprostol | 14 | 54.9 | 55.0 |
| Felodipine Extended-Release Tablets | 14 | 46.9 | 47.0 |
| Felodipine | 14 | 46.9 | 47.0 |
| Ado-Trastuzumab Emtansine | 9 | 40.4 | 40.4 |
| Lapatinib | 16 | 39.5 | 39.5 |
| Pertuzumab | 18 | 25.4 | 25.5 |
| Lurasidone Hydrochloride | 13 | 23.7 | 23.7 |
| Erlotinib | 5 | 19.4 | 19.4 |
| Erlotinib Hydrochloride | 6 | 18.0 | 18.0 |
| Emicizumab | 4 | 12.1 | 12.1 |
| Guselkumab | 7 | 7.4 | 7.4 |